Click on a client name to learn more.

Aptuit, Inc. is a company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. The company was founded by a group of industry experts with extensive market experience, who have a track record of building a similar, highly successful company through acquisitions and investment. Aptuit recently completed two significant acquisitions, Quintiles Early Development and Packaging business units and Almedica International, firmly establishing the Company as a leading player in the provision of drug development services and the largest global provider of clinical packaging and logistics services by capacity.

 Website: www.aptuit.com

BioFlorida, Florida’s independent statewide bioscience organization, serves its members by providing the infrastructure to exchange information and ideas through industry specific programming, education, networking and legislative initiatives. The organization focuses on creating and maintaining a favorable business and legislative environment, advancing the commercialization of research and working with investors, private enterprise, government, academia and the financial and service sectors to further develop existing companies, launch start-up companies and attract new biotechnology business to Florida.

 Website: www.bioflorida.org

BioHouston, is a non-profit organization of the Houston’s major research, healthcare and higher education institutions, local government and economic development entities, life science companies and venture capital firms. BioHouston’s core activities fall into three complementary categories:

• Increase access to early-stage capital;
• Support and encourage entrepreneurship among regional cluster participants or potential participants; and
• Provide support for the life science community, with the aim of building a vibrant life science economic cluster.

 Website: www.biohouston.org

BioMarin focuses on developing and commercializing first-to-market biopharmaceuticals to improve the lives of people living with life-threatening diseases or serious medical conditions. The company focuses on products that can be brought to market relatively quickly and to support this strategy, selects product candidates for diseases and conditions that have well-understood biology, represent a clear, unmet medical need, and have a clear-cut clinical development profile.

 Website: www.biomarinpharm.com

BioTrove, Inc. is a biotechnology company focused on advancing life science and drug discovery research by leveraging revolutionary micro- and nano-scale technologies. BioTrove has two core platforms: the Living Chip™,a broadly applicable nano-liter fluidics technology platform for massively parallel and low-volume analysis of genetic, genomic, proteomic, biochemical and cellular samples and Momentum™ Assay Development and Screening, an assay development and high throughput screening service that unlocks the value of intractable drug targets.

 Website: www.biotrove.com

Cerus Corporation develops novel products for cancer, infectious diseases and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next-generation immunotherapies – an attenuated Listeria platform is being used to develop anti-cancer immunotherapies and their Helinx KBMA platform is providing the a mechanism for developing anti-infective immunotherapies. Cerus’ INTERCEPT Blood System products enhance the safety of blood components for patients who require transfusions of platelets, plasma and red blood cell. Through proprietary pathogen inactivation both identified and unidentified bacteria and viruses are removed.

 Website: www.cerus.com

Chiron is a multi-dimensional company with businesses in biopharmaceuticals, vaccines and blood testing. With more than 50 products to detect, prevent and treat diseases, marketed through the company's three global business units: Blood Testing, Vaccines and BioPharmaceuticals, Chiron delivers innovative and valuable products to protect human health. The company works to deliver on the limitless promise of science and make a positive difference in people's lives.

 Website: www.chiron.com

Adnexus Therapeutics, Inc. develops the next generation of protein-based drugs through the use of an advanced product platform for engineering new proteins. The company's novel protein drugs are being developed with superior therapeutic properties, including higher potency, greater specificity, and less frequent dosing than conventional protein drugs.

At the core of the Company's sophisticated drug discovery platform is the established protein display technology, PROfusion™, which Compound Therapeutics' employs to engineer new proteins in major disease areas. The company's discovery platform is the foundation for a product-generating capability that synthesizes novel biotherapeutics including proprietary binding proteins (AdNectins) and binding proteins linked to enzymes, called Target Addressable Enzymes (Adzymes).

 Website:  www.compoundtherapeutics.com

Curis is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis product development involves using proteins or small molecules to modulate these pathways, for example, increasing the pathway signals when they are insufficient or decreasing them when they are excessive. Curis has successfully used this technology and product development strategy to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, hair growth regulation, and cardiovascular disease.

 Website: www.curis.com

Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation.

 Website: www.cyclacel.com

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

 Website: www.epicept.com

FoldRx Pharmaceuticals (FoldRx) is a discovery and development company focusing on first in class disease-modifying small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). Protein misfolding is increasingly being recognized as an underlying cause in many chronic degenerative diseases. By applying FoldRx's proprietary expertise in protein folding and its platform for drug and target discovery, the Company is building a pipeline, initially for neurodegenerative and cardiovascular conditions. FoldRx's initial pipeline includes a program in advanced pre-clinical development to treat a genetic cardiovascular disorder, Familial Amyloid Cardiomyopathy (FAC), and a discovery program in Parkinson's disease.

 Website: www.foldrx.com

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company's four most advanced programs are in sickle cell disease, epilepsy and neuropathic pain, atrial fibrillation, and dementia. Icagen is also conducting ongoing drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders and glaucoma.

 Website: www.icagen.com

The Massachusetts Biotechnology Council (MBC), founded in 1985, is a not-for-profit organization that provides services and support for the Massachusetts biotechnology industry. The MBC is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 500 companies, academic institutions and service organizations involved in life sciences and health care, the MBC works with public leaders to advance policy and promote education, while providing member programs and events, industry information, and services.

 Website: www.massbio.org

MedQuist is the world's leading medical transcription service provider and the premier supplier of dictation, transcription, speech recognition and coding products and services. Whether you prefer outsource services, an on-premise installation of software and hardware or a combination, MedQuist is the answer. Our flexible blend of quality service combined with advanced technology allows you to construct the solution that fits your exact needs.

 Website: www.medquist.com

OMRIX, a commercial-stage biopharmaceutical company, develops and markets innovative biosurgical and antibody-based products, utilizing its proprietary protein purification technology and manufacturing know-how. As part of its business strategy, OMRIX commercializes certain biosurgical products through collaborations with companies whose marketing and sales expertise are a complement to OMRIX's own areas of specialty. OMRIX' novel and easy-to-use Fibrin Patch, a biological-device convergence product candidate, addresses unmet medical needs.

 Website: www.omrix.com

Oxxon Therapeutics, Inc. (Oxxon) is advancing the next generation of innovative immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the Company has built a pipeline through its proprietary PrimeBoost platform, an approach that allows the rapid development of products to selectively stimulate and enhance a potent cellular immune response. The Company has five development programs in hepatitis, melanoma and HIV, two of which are in Phase II clinical trials. In addition, the company is leveraging its enabling platform through partnerships with companies and academic collaborations.

The PrimeBoost platform, for which the company has received broad patent coverage, is based on a two-stage treatment regimen; a priming component containing a disease antigen(s) to stimulate the immune system to produce disease-specific T cells, followed by a boosting component, containing the same antigen(s), delivered in a non-replicating vector. The boost amplifies the disease-specific T cell population to target and destroy diseased cells without harming normal cells.

 Website: www.oxti.com

PathWork Informatics is at the forefront of a revolution in personalized diagnostics. Our proprietary analytics and delivery platform will transform gene expression profiles into highly predictive molecular diagnostics for clinical laboratories, oncologists, and their patients. The Company's first in a series of novel diagnostic solutions will identify the unknown or uncertain primary site of origin in cancer patients. Founded in 2003, PathWork Informatics is a privately-held company located in San Jose, California.

 Website:
www.pathworkinformatics.com/

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA members invested an estimated $38.8 billion in 2004 in discovering and developing new medicines. PhRMA companies are leading the way in the search for new cures.

PhRMA’s mission is to conduct effective advocacy for public policies that encourages innovation and discovery of important new medicines for patients by pharmaceutical/
biotechnology research companies.

 Website: www.phrma.org

ProEthic is an emerging specialty pharmaceutical company enhancing treatment strategies initially in the areas of pain and migraine. Founded in 2001, the privately held company focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical products. ProEthic also markets niche generic prescription pharmaceutical products through Midlothian Laboratories LLC, a wholly owned subsidiary.

 Website: www.proethic.com/intro.swf

Transport Pharmaceuticals is revolutionizing the treatment of dermal diseases through the development of a proprietary drug delivery platform that combines iontophoretic technology with topical drugs significantly enhancing their effectiveness. Transport’s technology is applicable to multiple dermatological diseases, with an initial target of herpes labialis, also known as cold sores. Transport’s product delivers medication locally through the skin, using a small, handheld device and a unit dose, disposable medication applicator. The combination product allows patients to self-administer topical drugs for a variety of indications.

 Website: www.transportpharma.com

Zymenex is engaged in the research and development of innovative therapeutics for life threatening diseases.

The initial goal is to develop a successive number of enzyme replacement therapies for diseases, which may have an Orphan Drug potential.

During the development phases, Zymenex has outsourced R&D tasks to subcontractors where feasible. This has allowed the company to shorten development times, limit costs and seek out the best contract expertise worldwide.

 Website: www.zymenex.com